<DOC>
	<DOCNO>NCT02837900</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability , preliminary efficacy second course TPX-100 administer intra-articular injection subject osteoarthritis knee participate study TPX-100-1 .</brief_summary>
	<brief_title>A Study Evaluating Safety Efficacy Second Course TPX-100 Subjects Who Previously Received TPX-100 Patellar Osteoarthritis Involving Both Knees</brief_title>
	<detailed_description>Recruit 70 subject participate protocol TPX-100-1 . The oppose knee treat get 200mg 4 weekly injection . The knee treat TPX-100-1 get randomize either 200mg dose placebo lookalike . The investigator follow subject 6 month . Two MRIs bi-lateral knee assess . Also collection ADA sample 4 time point 6 month period .</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis , Knee</mesh_term>
	<criteria>1 . Previous enrollment study TPX1001 Cruciate collateral ligament stability define clinical examination 2 . Able read , understand , sign date subject inform consent 3 . Willingness use acetaminophen primary analgesic ( painrelieving ) study medication injection period study day 30 . The maximum dose acetaminophen must exceed 2 grams/day ( 2000 mg per day ) . 4 . Willingness use hydrocodone hydrocodone/acetaminophen ( e.g . Norco ) breakthrough pain study day 30 . 5 . Willingness use nonsteroidal antiinflammatory drug ( NSAIDS ) aspirin , ibuprofen , naproxen study day 30 . 6 . Female subject child bear potential sexually active ( nonabstinent ) must agree comply use 2 highly effective method birth control ( oral contraceptive , implant , injectable indwell intrauterine device , condom spermicide , sexual abstinence ) participate study . 1 . `` Possibly , probably definitely '' drugrelated SAEs TPX1001 ; severe ongoing `` possibly , probably definitely '' relate AEs TPX1001 . 2 . Contraindication MRI , include : metallic fragment , clip device brain , eye , spinal canal ; implant device magnetically program ; weight &gt; 300 lb . ; moderate severe claustrophobia ; previous intolerance MRI procedure 3 . Prior surgery knee , exclude procedure debridement ( previous microfracture procedure ) 4 . Joint replacement knee surgery plan next 12 month 5 . History rheumatoid arthritis , psoriatic arthritis , autoimmune infectious cause arthritis 6 . Knee effusion &gt; 2+ follow clinical scale : Zero = No wave produce downstroke Trace = Small wave medial side downstroke 1+ = Larger bulge medial side downstroke 2+ = Effusion spontaneously return medial side upstroke ( downstroke necessary ) 3+ = So much fluid possible move effusion medial aspect knee screen 7 . Last viscosupplementation ( e.g . SynviscÂ® similar hyaluronic acid product ) inject either knee &lt; 3 month screen 8 . Last intraarticular knee injection corticosteroid &lt; 2 month screen 9 . Use steroid ( except inhale corticosteroid respiratory problem ) previous month screen 10 . Known hypersensitivity TPX100 11 . Known hypersensitivity acetaminophen hydrocodone 12 . History arthroscopy either knee last 3 month screen 13 . History septic arthritis , gout pseudogout , either knee previous year screen 14 . Clinical sign acute meniscal tear ( lock , new acute mechanical symptom consistent meniscal tear ) 15 . Patellar chondrocalcinosis XRay 16 . Skin problem , rash hypersensitivity , affect either knee injection site 17 . Bleeding problem , platelet coagulation deficiency contraindicating , doctor 's opinion , intraarticular injection 18 . Active systemic infection 19 . Current treatment treatment within previous 2 year prior Screening Visit malignancy except basal cell squamous cell carcinoma skin , unless specific write permission provide Sponsor 's medical monitor 20 . Women childbearing potential pregnant , nursing , plan become pregnant , agree remain acceptable method birth control throughout entire study period 21 . Participation clinical osteoarthritis drug study , exception TPX1001 , within one year prior screen 22 . Currently take Paclitaxel ( mitotic inhibitor ) , natalizumab ( antiintegrin monoclonal antibody ) , antiintegrin treatment . 23 . History significant liver disease consumption 3 alcoholic drink day . ( Definition one alcoholic drink : 12ounces beer , 8ounces malt liquor , 5ounces wine , 1.5ounces `` shot '' 80proof distil spirit liquor gin , rum , vodka , whiskey ) .</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>